m6A-centered Crosstalk Information
Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
| Crosstalk ID |
M6ACROT02047
|
[1] | |||
m6A modification
MALAT1
MALAT1
METTL3
Methylation
 : m6A sites
Indirect
Enhancement
DNA methylation
DNMT3A
SFRP2
|
|||||
| m6A Modification: | |||||
|---|---|---|---|---|---|
| m6A Regulator | Methyltransferase-like 3 (METTL3) | WRITER | |||
| m6A Target | Metastasis associated lung adenocarcinoma transcript 1 (MALAT1) | ||||
| Epigenetic Regulation that have Cross-talk with This m6A Modification: | |||||
| Epigenetic Regulation Type | DNA methylation (DNAMeth) | ||||
| Epigenetic Regulator | Cysteine methyltransferase DNMT3A (DNMT3A) | WRITER | View Details | ||
| Regulated Target | Secreted frizzled-related protein 2 (SFRP2) | View Details | |||
| Crosstalk Relationship | m6A → DNA methylation | Enhancement | |||
| Crosstalk Mechanism | m6A modification indirectly regulates DNA methylation through downstream signaling pathways | ||||
| Crosstalk Summary | METTL3 stabilized Metastasis associated lung adenocarcinoma transcript 1 (MALAT1) expression by promoting m6A modification of MALAT1. MALAT1 promoted Secreted frizzled-related protein 2 (SFRP2) methylation and led to reduced SFRP2 expression by recruiting DNMT1, DNMT3A, and DNMT3B to the promoter region of SFRP2. Furthermore, SFRP2 facilitated activation of the Wnt/beta-catenin signaling. By this mechanism, METTL3 suppressed autism-like symptoms and hippocampal neuron apoptosis. | ||||
| Responsed Drug | Simvastatin | ||||
| In-vivo Model | Healthy adult ICR male (aged: 8 weeks old; weighing: 40- 70 g) and female mice (aged: 8 weeks old; weighing: 40-60 g) were obtained from Hunan SJA Laboratory Animal Co., Ltd. (Hunan, China). These mice were housed in the SPF laboratory at 25 ° C and 55% humidity under a 12-h light/dark cycle, with ad libitum access to food and water for acclimatization. | ||||
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
| Cysteine methyltransferase DNMT3A (DNMT3A) | 8 Compound(s) Regulating the Target | Click to Show/Hide the Full List | ||
 Compound Name |
PMID27376512-Compound-Figure3CN | Patented | [2] | |
|---|---|---|---|---|
| MOA | Inhibitor | |||
| Activity | EC50 = 1100 nM | |||
| External Link | ||||
| Compound Name |
PMID27376512-Compound-Figure3CG | Patented | [2] | |
| MOA | Inhibitor | |||
| Activity | EC50 = 2400 nM | |||
| External Link | ||||
| Compound Name |
PMID27376512-Compound-Figure3CM | Patented | [2] | |
| MOA | Inhibitor | |||
| Activity | EC50 = 1100 nM | |||
| External Link | ||||
| Compound Name |
PMID27376512-Compound-Figure2aExample1 | Patented | [2] | |
| MOA | Inhibitor | |||
| Activity | IC50 = 3000 nM | |||
| External Link | ||||
| Compound Name |
PMID27376512-Compound-MTC-424 | Patented | [2] | |
| MOA | Inhibitor | |||
| Activity | IC50 = 1940 nM | |||
| External Link | ||||
| Compound Name |
PMID27376512-Compound-MTC-427 | Patented | [2] | |
| MOA | Inhibitor | |||
| Activity | IC50 = 295 nM | |||
| External Link | ||||
| Compound Name |
PMID27376512-Compound-MTC-422 | Patented | [2] | |
| MOA | Inhibitor | |||
| Activity | IC50 = 1430 nM | |||
| External Link | ||||
| Compound Name |
PMID27376512-Compound-MTC-423 | Patented | [2] | |
| MOA | Inhibitor | |||
| Activity | IC50 = 363 nM | |||
| External Link | ||||
References